Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Aldeyra Therapeutics, Inc. following a significant stock price drop after the FDA's response regarding their investigational drug candidate reproxalap [1][2]. Group 1: Company Overview - Aldeyra Therapeutics, Inc. is focused on developing reproxalap for the treatment of dry eye disease [2]. - The company received a Complete Response Letter from the FDA indicating that the New Drug Application (NDA) for reproxalap did not demonstrate adequate efficacy [2]. Group 2: FDA Response and Stock Impact - The FDA's Complete Response Letter highlighted that no manufacturing or safety issues were found, but the NDA failed to show efficacy in well-controlled studies [2]. - Following the FDA's announcement, Aldeyra's stock price plummeted by $3.90, a decrease of 73.31%, closing at $1.42 per share on April 3, 2025 [2]. Group 3: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of investors regarding potential securities fraud by Aldeyra and its officers or directors [1]. - The firm has a long history in corporate and securities class litigation, having recovered significant damages for victims of securities fraud [3].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving Gorilla Technology Group, Inc. following a significant stock price drop after a critical report [1][2]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Gorilla Technology Group, Inc. and is looking into allegations of securities fraud or other unlawful business practices by the company and its officers [1]. - The investigation was prompted by a short report from The Bear Cave, which highlighted "red flags" regarding Gorilla's aggressive shift to AI technology and concerns over financial reporting [2]. Group 2: Stock Performance - Following the publication of the short report, Gorilla's stock price decreased by $13.50 per share, representing a decline of 32.21%, closing at $28.41 per share on March 7, 2025 [2]. Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [3].

Core Viewpoint - A class action lawsuit has been filed against Intellia Therapeutics, Inc. for alleged violations of securities laws, specifically related to misleading statements about the development of its drug NTLA-3001 [1][4]. Group 1: Lawsuit Details - The lawsuit is based on claims that Intellia made false and misleading statements regarding its drug development and marketing strategies, particularly concerning NTLA-3001 [4]. - Investors who purchased Intellia's securities between July 30, 2024, and January 8, 2025, are encouraged to participate in the class action [2]. - The class has not yet been certified, meaning that potential class members are not currently represented by an attorney [3]. Group 2: Allegations Against the Company - The complaint alleges that Intellia provided investors with a false impression of having reliable information about NTLA-3001's development [4]. - It is claimed that the company's reports on timelines for future studies were unsustainable due to high costs and inefficient delivery methods [4]. - The company reportedly struggled to provide timely doses of NTLA-3001 and maintain adequate staffing levels, leading to materially misleading public statements [4].

NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against The Trade Desk, Inc. (NASDAQ: TTD) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Trade Desk, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/the-trade-desk-inc Investors have until April 21, 2025, to ask the Court to be appoin ...

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims against Block, Inc. to hold its officers and directors accountable for alleged damages caused to the company [1] Group 1: Legal Rights and Shareholder Information - Shareholders who owned Block, Inc. shares before February 26, 2020, may have legal rights to pursue claims against the company's officers and directors [2] - A previous class action lawsuit was filed for shareholders who acquired stock between February 26, 2020, and April 30, 2024, excluding those who purchased shares before this period from recovery [2] Group 2: Allegations Against Block, Inc. - The complaint alleges that Block engaged in significant compliance failures at Square and Cash App, including inadequate due diligence on customer identities and transactions [3] - It is claimed that Block created an environment conducive to illegal activities by allowing minimal obligations for account creation and transactions, and by encouraging the use of bitcoin [3] - Allegations include that Block's platforms facilitated various illegal activities such as money laundering, child sexual abuse, sex trafficking, drug trafficking, and terrorism financing [3] - The complaint states that Block allowed customers to withdraw funds from flagged accounts and permitted multiple accounts to be opened using fake identities [3] - Block's leadership allegedly failed to address known compliance issues despite numerous warnings and complaints [3] - The complaint suggests that user metrics for Cash App were artificially inflated due to the presence of fake accounts [3] - As a result of these issues, Block faced undisclosed risks that could lead to reputational damage, regulatory actions, and negative impacts on operations and financial results [3]

Core Viewpoint - A class action securities lawsuit has been filed against The Trade Desk, Inc. for alleged securities fraud affecting investors between May 9, 2024, and February 12, 2025 [1] Group 1: Allegations and Impact - The lawsuit claims that The Trade Desk faced significant execution challenges in rolling out its AI forecasting tool, Kokai, which included transitioning clients from the older platform, Solimar [2] - These execution challenges reportedly delayed the Kokai rollout and negatively impacted the company's business operations, particularly revenue growth [2] - Positive statements made by the defendants regarding the company's business and prospects were allegedly materially false and misleading due to the aforementioned issues [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until April 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - Securities class action lawsuits have been filed against The Trade Desk, Inc. for allegedly making materially false and misleading statements regarding its business operations and the rollout of its new platform, Kokai, during the specified Class Period from May 9, 2024, to February 12, 2025 [1][2]. Group 1: Allegations Against The Trade Desk - Defendants are accused of failing to disclose significant execution challenges related to the Kokai rollout, which involved transitioning clients from the older platform, Solimar [2]. - The execution challenges reportedly delayed the Kokai rollout and negatively impacted the company's business and revenue growth [2]. - Positive statements made by the defendants about the company's operations and prospects are claimed to be materially misleading and lacking a reasonable basis [2]. Group 2: Lead Plaintiff Process - Investors in The Trade Desk have until April 21, 2025, to seek appointment as a lead plaintiff representative for the class action [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3].

Core Viewpoint - A class action securities lawsuit has been filed against The Trade Desk, Inc. for alleged securities fraud affecting investors between May 9, 2024, and February 12, 2025 [1] Group 1: Allegations and Impact - The lawsuit claims that The Trade Desk faced significant execution challenges in rolling out its AI forecasting tool, Kokai, which included transitioning clients from the older platform, Solimar [2] - These execution challenges reportedly delayed the Kokai rollout, negatively impacting the company's business operations and revenue growth [2] - Positive statements made by the defendants regarding the company's business and prospects were allegedly materially false and misleading due to the aforementioned issues [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until April 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against The Trade Desk, Inc. (NASDAQ: TTD) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Trade Desk, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/the-trade-desk-inc. Investors have until April 21, 2025, to ask the Court to be appoin ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Xponential Fitness, Inc. and its officers or directors following the company's disappointing financial results and subsequent stock price drop [1][3]. Financial Performance - On March 13, 2025, Xponential reported an unexpected loss for the fourth quarter and a 7.7% year-over-year revenue decline [3]. - The company's Board of Directors announced that the financial statements for the fiscal year ended December 31, 2023, would need to be restated [3]. - Following these announcements, Xponential's stock price fell by $4.66 per share, or 38.45%, closing at $7.46 per share on March 14, 2025 [3]. Legal Investigation - Pomerantz LLP is actively investigating claims on behalf of investors of Xponential Fitness, Inc. regarding possible securities fraud [1]. - Investors are encouraged to contact Pomerantz LLP for more information about the investigation [1].